Revance Therapeutics (RVNC) Received its Third Buy in a Row

After Mizuho Securities and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Serge Belanger maintained a Buy rating on Revance Therapeutics today and set a price target of $32.00. The company’s shares closed last Monday at $15.81.

According to, Belanger is a 1-star analyst with an average return of -1.3% and a 43.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.

Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.33, which is an 113.0% upside from current levels. In a report issued on October 30, Wells Fargo also upgraded the stock to Buy with a $20.00 price target.

See today’s analyst top recommended stocks >>

Based on Revance Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.39 million. In comparison, last year the company had a GAAP net loss of $32.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts